Model: C57BL/6 mice
Dosage: 500 mg/kg/day of SRN-901 via oral gavage for six days per week starting at 18 months of age; 14.4 ppm of rapamycin mixed in food starting at 18 months of age; 300 mg/kg/day of NMN via oral gavage for six days per week starting at 18 months of age; and 300 mg/kg/day of NR via oral gavage for six days per week starting at 18 months of age

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

In a newly published mouse study, SRN-901 extended remaining lifespan by 33%, slowed frailty progression, and lowered tumor incidence.

Seragon’s SRN-901 extended the remaining lifespan of adult mice by 33%, attenuated frailty progression by 70%, and reduced tumor incidence by 30.53%, according to a newly published preclinical study.

Aging &amp; Longevity

Model: C3B6F1 hybrid mice 
Dosage: 42 mg/kg of rapamycin and 1.44 mg/kg of trametinib in food starting at 6 months of age

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29% in female mice and 27% in male mice, respectively.

(The study’s lead author, Linda Partridge | The Biologist)

Combining two cancer treatment drugs, trametinib and rapamycin, extends lifespan by 29% and 27% in middle-aged female and male mice, respectively.

Model: C57BL/6N male mice 
Dosage: AIN-93 M diet with 0.025% (15 mg/kg per day) niclosamide for the Old + NL group or 0.050% (30 mg/kg per day) niclosamide for the Old + NH group, starting at 12 months of age to 21 months of age

Drug Approved Against Tapeworms May Counteract Aging, Suggests New Study

New research suggests niclosamide, approved for human use against tapeworms, alleviates frailty and suppresses the protein complex mTOR, which regulates cell growth, in aged mice.

(The drug niclosamide | Hospital Pharmacy Europe)

Niclosamide, an agent approved for human use against tapeworms, alleviates age-related frailty, suppresses mTOR, and activates autophagy in old mice.

Seragon’s RESTORIN and the Evolution of Aging Interventions Containing NAD+ Precursors

Aging interventions that include NAD+ precursors have evolved, adding components targeting various hallmarks of aging, from inflammation to cell waste elimination.

Some aging intervention products with NAD+ precursors, like Seragon’s Restorin, have evolved to include additional components targeting multiple hallmarks of aging.

The large-scale preclinical study shows that SRN-901 significantly extends lifespan and healthspan while improving a great number of aging parameters.


Seragon Biosciences increases the lifespan and healthspan of mice in one of the largest studies of its kind. 

Search Result: SRN-901

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Drug Approved for Humans Against Tapeworms May Counteract Aging, Similar to Rapamycin, Suggests New Study

Seragon’s RESTORIN and the Evolution of Aging Interventions Containing NAD+ Precursors

Seragon’s Aging Intervention Drug SRN-901 Achieves One of the Largest Extensions of Lifespan and Healthspan to Date